關(guān)鍵詞： GSK Sanderling
2013年1月11日訊 /生物谷BIOON/ --GlaxoSmithKline公司將可能將發(fā)展目光投向美國(guó)西部,。GSK近日在San Francisco召開(kāi)的J.P. Morgan confab上表示公司現(xiàn)已投入5000萬(wàn)美元和Sanderling Ventures公司共同設(shè)立了一個(gè)總額達(dá)2億5千萬(wàn)的基金專(zhuān)門(mén)用于支持新的生物技術(shù)企業(yè)的建立。
Glaxo公司的Melinda Stubbee表示這次的投資配合早先GSK在Index Ventures公司的投資將在公司在美國(guó)西部的發(fā)展計(jì)劃中起到重要作用。而Sanderling公司自從1979年建立以來(lái)已經(jīng)自助了90家企業(yè)的建立,，一些優(yōu)秀的企業(yè)如Dendreon公司,、Regeneron公司等都收到過(guò)其資助。近些年來(lái),，Sanderling公司在生物領(lǐng)域的投資漸趨謹(jǐn)慎,，最大一筆投資要追溯到2004年。這些年來(lái),，Sanderling公司將近一半的資金投給了新藥研發(fā)項(xiàng)目,，另一半則是支持了醫(yī)療設(shè)備和信息技術(shù)相關(guān)公司。（生物谷Bioon.com）
詳細(xì)英文報(bào)道:
GlaxoSmithKline ($GSK) is headed west. The drug giant revealed at the J.P. Morgan confab in San Francisco that it has put up $50 million of a $250 million life sciences fund that has been put together by San Mateo, CA-based Sanderling Ventures, which a spokesperson says will help fill a geographic gap in their strategy to seed new biotech startups.
Glaxo's Melinda Stubbee tells FierceBiotech that the fund will be a player in the western U.S., with GSK matching its earlier investments in Index Ventures, which is backing startups in Europe, the U.S, and Israel, and an innovation fund for Canada. This new fund is dubbed Sanderling 7, she adds. "They have" the money, she says, "but I can't say who" put up the rest.
Sanderling has backed about 90 upstarts since it opened its doors in 1979. Its portfolio includes big names such as Dendreon ($DNDN) and Regeneron ($REGN). Endocyte and Pacira went public, and Taligen was acquired by Alexion ($ALXN) for $111 million. GSK, meanwhile, has been acutely aware of the tough financing environment for biotech startups, which produce the kind of new ideas and technologies that the giants benefit from as well.
But Sanderling has kept a decidedly low profile in recent years. Its last fund--which raised $421 million--came together way back in 2004, a different era for the biotech industry. Funds traditionally look to put together new funds after about four years, so GSK's substantial backing must have come as a godsend for the rainmakers at the firm.
Sanderling has specialized in launching startups, with about half of its cash reserved for drug developers and the other half going to medical devices and information technology.
"We believe strongly that if you build a company, that's where the real significant return on investment comes," Sanderling's Robert McNeil told FierceBiotech several years ago. "Short term investing is not the best way to do things. We're in company-building mode."
